Alkermes Plc
A biopharmaceutical company that develops and sells medicines for central nervous system and addiction disorders, including Aristada for schizophrenia and Vivitrol for alcohol and opioid dependence. The name Alkermes comes from the alchemical word for a red dye made from insects, nodding to the firm's roots in drug-delivery technology. Founded in 1987 and headquartered in Dublin, it grew through the merger of two drug-delivery pioneers and now lists its shares on Wall Street.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 13G/APassive | 2.8% | 4.66M | May 15, 2026 |
| Vanguard Portfolio Management | 13GPassive | 5.8% | 9.65M | Apr 28, 2026 |
| Vanguard Capital Management | 13GPassive | 5.21% | 8.68M | Apr 28, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Baker Bros. Advisors LP | 13GPassive | 6.1% | 10.01M | Feb 17, 2026 |
| Baker Bros. Advisors (GP) LLC | 13GPassive | 6.1% | 10.01M | Feb 17, 2026 |
| Julian C. Baker | 13GPassive | 6.1% | 10.01M | Feb 17, 2026 |
| Felix J. Baker | 13GPassive | 6.1% | 10.01M | Feb 17, 2026 |
| STATE STREET CORPORATION | 13GPassive | 5.2% | 8.54M | Nov 10, 2025 |
| BlackRock, Inc. | 13G/APassive | 15.8% | 25.64M | Apr 28, 2025 |